A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Protocol No
ACCRU-SC-1601
Principal Investigator
Lisa Baumann Kreuziger
Phase
III
Summary
It is known that having cancer and receiving treatment for cancer can cause side effects, such as blood clots. The purpose of this research study is to compare the effects, good and/or bad, of two different doses of apixaban (Eliquis®) 2.5 mg or 5 mg on you and your blood clot, to find out which is better in preventing and treating blood clots. In this study, the patient will get either apixaban 2.5 mg or 5 mg twice daily.
Description
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: